Heart rate reduction with esmolol is associated with improved arterial elastance in patients with septic shock: a prospective observational study
- 3.4k Downloads
Ventricular–arterial (V–A) decoupling decreases myocardial efficiency and is exacerbated by tachycardia that increases static arterial elastance (Ea). We thus investigated the effects of heart rate (HR) reduction on Ea in septic shock patients using the beta-blocker esmolol. We hypothesized that esmolol improves Ea by positively affecting the tone of arterial vessels and their responsiveness to HR-related changes in stroke volume (SV).
After at least 24 h of hemodynamic optimization, 45 septic shock patients, with an HR ≥95 bpm and requiring norepinephrine to maintain mean arterial pressure (MAP) ≥65 mmHg, received a titrated esmolol infusion to maintain HR between 80 and 94 bpm. Ea was calculated as MAP/SV. All measurements, including data from right heart catheterization, echocardiography, arterial waveform analysis, and norepinephrine requirements, were obtained at baseline and at 4 h after commencing esmolol.
Esmolol reduced HR in all patients and this was associated with a decrease in Ea (2.19 ± 0.77 vs. 1.72 ± 0.52 mmHg l−1), arterial dP/dt max (1.08 ± 0.32 vs. 0.89 ± 0.29 mmHg ms−1), and a parallel increase in SV (48 ± 14 vs. 59 ± 18 ml), all p < 0.05. Cardiac output and ejection fraction remained unchanged, whereas norepinephrine requirements were reduced (0.7 ± 0.7 to 0.58 ± 0.5 µg kg−1 min−1, p < 0.05).
HR reduction with esmolol effectively improved Ea while allowing adequate systemic perfusion in patients with severe septic shock who remained tachycardic despite standard volume resuscitation. As Ea is a major determinant of V–A coupling, its reduction may contribute to improving cardiovascular efficiency in septic shock.
KeywordsTachycardia Septic shock Beta-adrenergic receptors Heart rate Arterial elastance Dicrotic notch Ventricular-arterial coupling
Compliance with ethical standards
Conflicts of interest
Andrea Morelli received honoraria for speaking at Baxter symposia. Mervyn Singer served as a consultant and received honoraria for speaking and chairing symposia for Baxter. Salvatore Mario Romano has a patent “Method and apparatus for measuring cardiac flow output” (USA Patent Number 6758822). No other disclosures were reported.
- 22.Sunagawa K, Maughan WL, Burkhoff D, Sagawa K (1983) Left ventricular interaction with arterial load studied in the isolated canine ventricle. Am J Physiol 245:H733–H788Google Scholar
- 28.Pemberton P, Veenith T, Snelson C, Whitehouse T (2015) Is it time to beta block the septic patient? Biomed Res Int. doi: 10.1155/2015/424308